The research team systematically searched five major sources of clinical evidence, including PubMed, Embase, the Cochrane Central Register of Controlled Trials, PsycINFO and ClinicalTrials.gov, with no restrictions on publication date and primary searches conducted up to May 15, 2026. Their aim was to capture randomized controlled trials of six anti-obesity medications approved by either the United States Food and Drug Administration or the European Medicines Agency, restricted to trials in adults with overweight or obesity that reported mental health outcomes. The outcomes of interest fell into three domains: the severity of depressive symptoms, mental health-related quality of life as measured by the Mental Component Summary of the Short Form-36 Health Survey, and weight-specific quality of life captured by the Impact of Weight on Quality of Life-Lite questionnaire. After screening, eleven unique trials contributed data to at least one of the efficacy analyses.

Methodologically, the study is notable for its use of Bayesian random-effects network meta-analysis, a statistical framework that allows simultaneous comparison of multiple treatments even when head-to-head trials are scarce. Rather than relying only on direct comparisons between a drug and placebo, the technique builds a network of evidence in which treatments are linked through shared comparators, and Markov Chain Monte Carlo sampling generates estimates with credible intervals that express the range within which the true effect most plausibly lies. The authors also applied the GRADE framework to rate the certainty of the evidence, and they registered the review prospectively on PROSPERO under identifier CRD420261400491, a detail that matters because it locks the analytic plan in place before results were known.

The headline finding on depression is, in a word, uncertainty. For depressive symptom severity, neither naltrexone/bupropion, an oral combination drug that pairs an opioid antagonist with an antidepressant, nor orlistat, the lipase inhibitor that blocks fat absorption in the gut, showed an effect clearly distinguishable from placebo. The standardized mean difference for naltrexone/bupropion was 0.03 with a 95 percent credible interval stretching from −0.93 to 0.90, an interval so wide it encompasses everything from a large benefit to a large harm. Orlistat fared similarly, with an estimate of −0.46 and a credible interval from −2.01 to 1.16. In plain terms, the randomized evidence assembled to date simply cannot establish whether these drugs improve mood, worsen it, or leave it untouched.

The picture for the incretin-based injectables was similarly inconclusive on general mental quality of life. For the SF-36 Mental Component Summary, the point estimates for semaglutide, liraglutide and tirzepatide all leaned modestly positive, at standardized mean differences of 0.20, 0.18 and 0.17 respectively, but every credible interval crossed the null. Semaglutide’s interval ran from −0.22 to 0.64, liraglutide’s from −0.38 to 0.74, and tirzepatide’s from −0.14 to 0.48. These are the kinds of results that should temper sweeping claims in either direction. There is no signal here of the catastrophic psychiatric deterioration feared in some early social media commentary, but neither is there statistical license to describe these drugs as mood lifters.

Where the analysis did find a consistent and statistically robust effect was in weight-specific quality of life, and this is arguably the study’s most clinically meaningful contribution. Tirzepatide showed the largest estimated improvement on the IWQOL-Lite total score, with a standardized mean difference of 0.63 and a credible interval of 0.44 to 0.87, comfortably excluding the null. Liraglutide followed with an estimate of 0.30, interval 0.03 to 0.53, and naltrexone/bupropion with 0.26, interval 0.03 to 0.48. This outcome measures how much a person’s weight interferes with daily living, physical function, self-esteem, sexual life and public distress, and it is precisely the domain where patients report the most tangible benefits of losing weight. The authors are careful to note, however, that treatment rankings do not establish clinical superiority, and the certainty of evidence across all outcomes ranged from moderate down to very low.

Perhaps the most striking gap the review exposes concerns psychiatric safety. Across the trials contributing to the adverse-event analysis, the evidence was described as sparse, and the tally of serious psychiatric events amounted to a single suicide or self-harm event among 4,216 participants. A denominator that small cannot support any firm conclusion about whether these medications raise or lower the risk of suicidal ideation and behavior, a question of genuine clinical importance given that bupropion carries its own psychiatric profile and that obesity itself is associated with elevated rates of depression. The GRADE assessments in the study reflect this fragility, and the authors explicitly state that psychiatric safety evidence remains too sparse for firm conclusions.

The technical machinery behind these conclusions deserves attention from anyone who follows evidence synthesis. The Bayesian approach allowed the team to propagate uncertainty through networks of trials rather than pretending that indirect comparisons are as reliable as direct ones, and the supplementary materials include convergence diagnostics, rank-probability distributions, surface-under-the-cumulative-ranking-curve values, leave-one-out sensitivity analyses and comparison-adjusted funnel plots to probe publication bias. Notably, the authors ran a sensitivity analysis on the SF-36 Mental Component Summary excluding the SURMOUNT-2 trial, indicating awareness that single large trials can dominate network estimates. This is the kind of methodological transparency that makes the review’s central message, one of evidentiary insufficiency rather than reassurance or alarm, credible.

Why does the evidence base remain so thin when millions of people are taking these drugs? The answer lies partly in trial design. Most pivotal obesity trials were powered to detect weight change, not psychiatric outcomes, and depression measures were often secondary, heterogeneous across trials, and captured with instruments ranging from the PHQ-9 and Beck Depression Inventory to the Hamilton Depression Rating Scale and the Hospital Anxiety and Depression Scale. Standardization of mental health endpoints, consistent follow-up durations, and prospective registration of psychiatric adverse-event definitions would all sharpen future inference. The authors call explicitly for future obesity trials to incorporate standardized depression, anxiety, suicidality and quality-of-life outcomes from the outset, a recommendation that echoes a broader movement in regulatory science toward making patient-reported mental health measures primary rather than incidental.

For clinicians and patients navigating the current wave of prescriptions, the practical takeaway is nuanced. The drugs most likely to change how a person feels about living in their body, in the specific sense of weight-related quality of life, appear to be tirzepatide, liraglutide and naltrexone/bupropion, with tirzepatide showing the largest and most certain effect. At the same time, neither benefit nor harm for depressive symptoms can be asserted from randomized evidence, and psychiatric safety monitoring should remain vigilant rather than complacent. The study, published open access on October 7, 2026, and funded without any specific grant from public, commercial or not-for-profit agencies, with the authors declaring no competing interests, does not diminish the therapeutic achievement of modern obesity medicine. Instead, it marks out precisely where the next generation of trials must go, reminding a field moving at extraordinary speed that the mind deserves the same measurement rigor as the waistline.

Subject of Research: Effects of approved anti-obesity medications on depression symptoms, psychiatric adverse events, and quality of life in adults with overweight or obesity

Article Title: Effects of approved anti-obesity medications on depression symptoms, psychiatric adverse events, and quality of life in adults who are overweight or obesity: a systematic review and Bayesian network meta-analysis

Article References: Peng, J., Sun, D., Yu, Y., Zhong, Q., Chang, X., Cao, L., Wu, C., Wang, R., Chen, H., Zhang, P., Su, Z., & He, Z. (2026). Effects of approved anti-obesity medications on depression symptoms, psychiatric adverse events, and quality of life in adults who are overweight or obesity: a systematic review and Bayesian network meta-analysis. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08721-7

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08721-7

Keywords: obesity, GLP-1 receptor agonists, tirzepatide, semaglutide, liraglutide, naltrexone/bupropion, depression, quality of life, network meta-analysis, psychiatric adverse events, BMC Psychiatry, systematic review

The research team, led by Jaeun Ahn and Joshua M. Sill of Eastern Virginia Medical School at Old Dominion University, together with colleagues at Jacobi Medical Center and National Cheng Kung University Hospital, drew on the TriNetX Global Collaborative Network, a federated health research platform aggregating de-identified records from more than 160 million patients across over 120 healthcare organizations worldwide. From this vast dataset, the investigators identified adults diagnosed with obstructive sleep apnea between January 2010 and November 2021 who had a body mass index above 30. Crucially, they excluded anyone with pre-existing heart failure, pulmonary hypertension, or myocardial infarction, ensuring that the outcomes they tracked were genuinely new events rather than complications of established disease.

The study design followed the conventions of a retrospective propensity score-matched cohort analysis. Patients prescribed a GLP-1 receptor agonist, specifically semaglutide, liraglutide, or dulaglutide, within one year of their sleep apnea diagnosis formed the exposed cohort, numbering 18,774 individuals. The comparison group comprised 847,137 patients with sleep apnea and obesity who were never prescribed any GLP-1 receptor agonist before or after diagnosis. Because the two groups differed substantially at baseline, with drug users tending to be heavier, more often female, and more likely to have elevated hemoglobin A1c, the researchers applied greedy nearest-neighbor propensity score matching to balance the cohorts on demographics, comorbidities, medications, BMI, and glycemic control. After matching, 18,523 patients remained in each arm, well balanced on every measured characteristic, including a mean age of roughly 55 years and a mean BMI near 40.8 in both groups.

Over a three-year follow-up period analyzed with Cox proportional hazards models, the differences between the groups were striking. New-onset heart failure, the primary outcome, occurred in 1,416 patients in the GLP-1 receptor agonist cohort versus 1,791 in the matched comparison group, corresponding to a 24 percent reduction in risk (hazard ratio 0.76, 95 percent confidence interval 0.71 to 0.82). Pulmonary hypertension showed an even larger relative reduction of 33 percent (hazard ratio 0.67). Acute myocardial infarction was likewise less frequent among drug users, with a hazard ratio of 0.76. Most dramatic of all was all-cause mortality: 550 deaths in the treated group against 945 in the untreated group, a 43 percent lower risk of dying from any cause (hazard ratio 0.57, 95 percent confidence interval 0.51 to 0.63). Ischemic stroke also trended lower, reaching statistical significance with a hazard ratio of 0.90.

Timing mattered as much as magnitude. Kaplan-Meier survival curves for heart failure, myocardial infarction, and death showed early separation between the two cohorts, a pattern the authors interpret as suggestive of direct cardiovascular benefits that extend beyond the slow, gradual effects of weight loss alone. If the drugs were working purely by shedding pounds, one might expect the curves to diverge only after substantial weight reduction had accumulated over many months. The early divergence instead hints at mechanisms acting more rapidly, such as improvements in endothelial function, reductions in systemic inflammation, and favorable hemodynamic changes. The pulmonary hypertension curve, by contrast, separated later, which is consistent with a benefit mediated more by sustained metabolic and weight-related improvements.

An exploratory subgroup analysis added an important layer of robustness. Each individual agent within the class was independently associated with lower heart failure risk: liraglutide with a hazard ratio of 0.73, dulaglutide with 0.75, and semaglutide with 0.83. The consistency across three chemically distinct molecules that share a common mechanism strengthens the biological plausibility of a class effect rather than an artifact tied to one particular drug. Most patients in the cohort received liraglutide (51.7 percent), followed by dulaglutide (35.0 percent) and semaglutide (19.1 percent), reflecting prescribing patterns during the study window, which predated the widespread adoption of higher-dose semaglutide formulations for weight management.

The findings arrive against a backdrop of rapidly evolving evidence on incretin-based therapies and sleep apnea. In the randomized SURMOUNT-OSA trial, tirzepatide, a dual agonist of the GLP-1 and GIP receptors, improved the apnea-hypopnea index, lowered high-sensitivity C-reactive protein, and reduced systolic blood pressure, pointing to multifaceted cardiometabolic effects. Recent meta-analyses have confirmed that GLP-1 receptor agonists and tirzepatide both significantly reduce the severity of sleep apnea. What has been missing, the authors argue, is direct evidence on hard cardiovascular endpoints, particularly incident heart failure, in patients with sleep apnea. This study addresses that gap using observational data, and its results align with the cardiovascular benefit profile these drugs established in large randomized trials among patients with type 2 diabetes, including SUSTAIN-6 for semaglutide, LEADER for liraglutide, and REWIND for dulaglutide.

The clinical context makes the results especially consequential. Positive airway pressure therapy remains the cornerstone of sleep apnea treatment, and prior research has explored its cardiovascular effects, though often in small samples; one frequently cited proof-of-concept study by O’Donnell and colleagues included only 30 participants. Many patients with obesity struggle to adhere to mask-based therapy, leaving a substantial residual risk population. If GLP-1 receptor agonists can serve as an adjunctive or alternative strategy, they could offer cardiovascular protection to patients who cannot or will not tolerate airway pressure devices, while simultaneously improving sleep-disordered breathing itself. The prospect of a single pharmacological intervention addressing obesity, apnea severity, and cardiovascular risk simultaneously is precisely what has made this drug class the focus of such intense scientific and public attention.

Yet the authors are careful to frame the findings as hypothesis-generating rather than definitive. The retrospective observational design precludes causal inference, and several clinically important variables were unavailable in the TriNetX database. The severity of sleep apnea, measured by the apnea-hypopnea index, was not captured, nor was adherence to positive airway pressure therapy, longitudinal weight trajectories, or the duration of diabetes. More severe apnea might independently prompt both higher cardiovascular risk and more aggressive treatment, and differential weight loss between the cohorts, expected given the drugs’ known effects, may have contributed to the outcome differences. Lifestyle factors such as alcohol consumption and exercise frequency were also unmeasured, leaving open the possibility of residual confounding. Reliance on administrative ICD-10 diagnosis codes introduces the potential for misclassification, although the authors note that such errors are likely nondifferential and would tend to bias the results toward the null, making the observed associations conservative estimates.

The researchers conclude that prospective studies are needed to validate the findings, ideally randomized controlled trials specifically evaluating the cardiovascular impact of GLP-1 receptor agonists in patients with obstructive sleep apnea and obesity, incorporating serial assessments of apnea severity, airway pressure therapy adherence, and body weight trajectories. Until such trials are completed, the study stands as one of the largest real-world examinations of these drugs in a sleep apnea population, and its message is hard to ignore: among more than 37,000 carefully matched patients, those taking GLP-1 receptor agonists were markedly less likely to develop heart failure, pulmonary hypertension, or heart attack, and markedly less likely to die. As prescriptions of these agents continue to climb worldwide, the question of whether they should be considered cardiovascular risk modifiers for the millions of obese patients with sleep apnea has moved from speculation toward the center of clinical debate.

Subject of Research: Cardiovascular effects of GLP-1 receptor agonists in obese patients with obstructive sleep apnea

Article Title: Glucagon-like peptide receptor agonists (GLP-1RAs) as cardiovascular risk modifiers in obstructive sleep apnea and obesity: a real-world study

Article References: Ahn, J., Song, J., Admire, K., Chang, Y., Chi, K.-Y., Gordon, N. T., & Sill, J. M. (2026). Glucagon-like peptide receptor agonists (GLP-1RAs) as cardiovascular risk modifiers in obstructive sleep apnea and obesity: a real-world study. Journal of Clinical Sleep Medicine, 22(1), Article 102. https://doi.org/10.1007/s44470-026-00110-x

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00110-x

Keywords: obstructive sleep apnea, GLP-1 receptor agonists, obesity, heart failure, pulmonary hypertension, cardiovascular risk, semaglutide, liraglutide, dulaglutide, propensity score matching, TriNetX, real-world evidence

To understand how a diabetes drug touches the vascular system, it helps to start with the hormone it mimics. GLP-1 is an incretin hormone released by enteroendocrine L-cells in the distal ileum and colon after a meal. When glucose or other nutrients arrive in the gut, these cells close ATP-dependent potassium channels, depolarize the membrane, open L-type calcium channels and secrete GLP-1 into the bloodstream. The hormone then amplifies insulin secretion from pancreatic beta cells by two- to three-fold compared with intravenous glucose, a phenomenon known as the incretin effect. It also delays gastric emptying and suppresses glucagon release. In type 2 diabetes, this incretin effect is blunted, partly through impaired GLP-1 function and reduced receptor expression, which is precisely why pharmacological boosting of the pathway has proven so effective.

Native GLP-1, however, is a fleeting molecule. The enzyme dipeptidyl peptidase-4 cleaves it within minutes, leaving a circulating half-life of roughly ninety seconds, so a substantial fraction of the hormone is inactivated before it ever reaches its targets. Therapeutic agonists were engineered to escape this fate. Exenatide, derived from a peptide found in the saliva of the Gila monster, survives for about 2.4 hours and was approved in 2005 for twice-daily injection. Liraglutide carries a fatty-acid side chain that binds reversibly to serum albumin, extending its half-life to 13 to 15 hours after subcutaneous injection. Semaglutide, dulaglutide and albiglutide push persistence further still, with half-lives long enough to permit once-weekly dosing. Tirzepatide adds a second layer of sophistication by engaging the receptor for the other incretin hormone, GIP, as well as GLP-1.

All of these molecules converge on a single target: the GLP-1 receptor, a class B G protein-coupled receptor of 463 amino acids found in the pancreas, gastrointestinal tract, lungs, kidneys, central nervous system and, in mice, monkeys and humans, the heart. When activated, the receptor can couple to the Gs protein to raise cyclic AMP, to Gq/11 to elevate intracellular calcium, and to beta-arrestin to trigger ERK1/2 signaling. Crucially, different ligands bias the receptor toward different downstream cascades, a property known as biased agonism. The review highlights this as one plausible explanation for why structurally distinct agonists do not lower blood pressure to the same degree: they are not simply switching the receptor on, they are steering it toward different intracellular programs.

The vascular story begins in the endothelium. In human umbilical vein endothelial cells exposed to GLP-1, receptor activation recruits the phosphatidylinositol 3-kinase/Akt pathway, which phosphorylates and activates endothelial nitric oxide synthase, raising the bioavailability of nitric oxide, the principal relaxing factor of the vessel wall. A parallel protein kinase A-dependent route to nitric oxide production operates alongside it. Together these converging pathways relax vascular smooth muscle and reduce peripheral resistance. Downstream, activation of AMP-activated protein kinase and suppression of nuclear factor-kappa B signaling cut vascular oxidative stress, adhesion molecule expression and inflammatory cytokine release, linking the acute vasoactive effects of the receptor to the slower, anti-atherosclerotic remodeling of the vessel wall.

The heart and kidneys contribute their own mechanisms. In atrial cardiomyocytes, GLP-1 receptor activation couples to Epac2, triggering the secretion of atrial natriuretic peptide, which raises cyclic GMP and promotes both vasodilation and renal sodium excretion. Direct natriuresis has been documented in healthy, obese and type 2 diabetic individuals, offering a plausible route by which plasma volume, and with it blood pressure, is reduced. Evidence from mouse studies further suggests that exendin-4 can dampen angiotensin II signaling in the kidney, inhibiting the transforming growth factor beta1 and Smad3 pathway that drives fibrosis. Yet here the literature fractures: a clinical study of dulaglutide found no significant changes in plasma renin activity, serum aldosterone or related neurohormonal markers, leaving the role of the renin-angiotensin-aldosterone system unresolved and flagged by the review as a priority for further investigation.

The clinical data, drawn from cardiovascular outcome trials and pooled analyses, paint a picture of modest but persistent effect. Exenatide at 10 micrograms twice daily reduced systolic pressure by a least-squares mean of 2.8 mmHg across 2,171 patients, with the largest difference, 8.2 mmHg versus placebo, seen in people whose baseline systolic pressure exceeded 150 mmHg. Once-weekly exenatide lowered systolic pressure by 1.6 mmHg in the EXSCEL trial of nearly 14,752 patients. Dulaglutide at 1.5 milligrams produced a 2 to 3 mmHg reduction evident within four weeks and sustained through 26 weeks, accompanied by a fall in 24-hour pulse pressure. Semaglutide at 1.0 milligram weekly lowered systolic pressure by 2.6 mmHg in SUSTAIN-6, and oral semaglutide matched that figure at week 83 in PIONEER-6. Liraglutide managed 1.2 mmHg over 36 months in LEADER, while lixisenatide achieved only 0.8 mmHg in ELIXA. Diastolic pressure, by contrast, was largely untouched.

Two patterns emerge from those numbers. First, the effect is drug-specific: agents differ by more than threefold in the magnitude of systolic reduction they deliver, consistent with the biased agonism observed at the receptor. Second, the benefit is conditional. People with normal blood pressure at baseline showed no between-group differences in the trials, suggesting that GLP-1 receptor agonists act as regulators of an elevated system rather than as blanket antihypertensives. The review also draws a careful temporal distinction that has muddied the literature. Acutely, GLP-1 receptor stimulation of sinoatrial node pacemaker cells and brainstem autonomic neurons raises heart rate and can transiently nudge mean arterial pressure upward, particularly after dose escalation. Chronically, sustained therapy produces a net systolic reduction as weight loss, improved glycemic control and the vascular, renal and anti-inflammatory mechanisms accumulate and outweigh the initial pressor response. The two effects operate on different timescales and are not contradictory, but conflating them has fueled apparent inconsistencies across studies.

What the mechanisms cannot yet claim is firm human validation. Aside from the natriuresis and endothelial function data, most of the mechanistic evidence comes from animal models and in vitro systems, and blood pressure was rarely a pre-specified primary endpoint in the major cardiovascular outcome trials from which the clinical numbers are extracted. That makes it difficult to determine whether the observed 1 to 3 mmHg reductions translate into meaningful antihypertensive benefit independent of glycemic control or weight loss, and head-to-head comparisons between agents are lacking. The review calls for trials that place blood pressure at the center of the design, translational studies in human subjects to confirm the proposed nitric oxide, atrial natriuretic peptide and renin-angiotensin pathways, and stratified analyses to identify which patients, most plausibly those with elevated baseline pressure and coexisting type 2 diabetes, stand to gain the most.

Even within those limits, the synthesis carries a striking implication. A drug class developed to restore a gut hormone signal has turned out to engage nearly every major axis of cardiovascular regulation: endothelial nitric oxide signaling, natriuretic peptide release, renal sodium handling, vascular inflammation and atherosclerotic plaque biology. Liraglutide has been shown to suppress angiotensin II-induced inflammatory cascades in vessel walls, preventing the expression of ICAM-1, VCAM-1 and P-selectin on endothelial cells and restoring nitric oxide levels. Exenatide modulates matrix metalloproteinases in human coronary artery cells and shifts macrophages from a pro-inflammatory M1 state toward a reparative M2 phenotype, stabilizing atherosclerotic lesions. Semaglutide and liraglutide reduce plaque development in mice through AMPK activation and lowered proinflammatory cytokines. The blood pressure effect, small as it is, may be the visible surface of a much deeper vascular reprogramming, and understanding it fully could determine how these blockbuster drugs are positioned in the broader campaign against cardiovascular disease.

Subject of Research: Blood pressure regulation by glucagon-like peptide-1 receptor agonists and its cardiovascular mechanisms

Article Title: Glucagon‐Like Peptide‐1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications

Article References: Alharbi, N. H. J. (2026). Glucagon‐Like Peptide‐1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications. Pharmacology Research & Perspectives, 14(5), Article e70329. https://doi.org/10.1002/prp2.70329

Image Credits: AI Generated

DOI: 10.1002/prp2.70329

Keywords: GLP-1 receptor agonists, blood pressure, hypertension, type 2 diabetes, nitric oxide, endothelial function, natriuresis, atrial natriuretic peptide, cardiovascular outcomes, semaglutide, liraglutide, incretin effect

Traumatic brain injury remains one of the leading causes of death and long-term disability worldwide, and for patients whose injuries require surgical intervention, such as evacuation of an intracranial hematoma, the prognosis is often grim. Neurosurgeons can relieve pressure on the brain and remove life-threatening collections of blood, but the secondary injury cascade that follows the initial trauma, involving inflammation, swelling, oxidative stress, and progressive damage to the blood-brain barrier, continues to unfold in the hours and days after the operation. Decades of clinical trials have failed to produce a pharmacological therapy that reliably improves outcomes after severe brain trauma, leaving supportive and surgical care as the mainstays of treatment. Against that backdrop, any signal that an existing, widely prescribed drug class might improve survival is bound to attract intense attention.

GLP-1 receptor agonists, which include drugs such as liraglutide and semaglutide, mimic the action of the gut hormone glucagon-like peptide-1, enhancing insulin secretion, suppressing appetite, and slowing gastric emptying. Their clinical success in metabolic disease has been extraordinary, but researchers have increasingly recognized that the GLP-1 receptor is not confined to the pancreas and the gut. Receptors for the hormone are found throughout the body, including in the brain, where they participate in insulin signaling, neuroinflammation, and neuronal survival pathways. This widespread expression has fueled speculation that GLP-1-based therapies could have effects far beyond glucose control, with investigations underway in conditions ranging from Parkinson’s disease and Alzheimer’s disease to stroke.

The biological rationale for a neuroprotective role in brain injury is substantial. A 2024 review in Signal Transduction and Targeted Therapy catalogued the mechanisms and therapeutic advances surrounding the GLP-1 receptor, highlighting its involvement in anti-inflammatory and cytoprotective signaling. The brain itself is an insulin-sensitive metabolic organ, as researchers Milstein and Ferris argued in Molecular Metabolism in 2021, meaning that metabolic hormones can directly influence neuronal function and resilience. In the context of trauma, this matters because the injured brain undergoes profound metabolic disruption: glucose metabolism becomes dysregulated, mitochondrial function falters, and the energy demands of repair collide with a compromised supply. Drugs that modulate insulin signaling and cellular stress responses could, in principle, tip the balance toward recovery rather than deterioration.

Laboratory studies have lent concrete support to that idea. In work published in PLOS ONE in 2015, Hakon and colleagues showed that liraglutide, a long-acting GLP-1 analogue, preserved the blood-brain barrier and protected cortical neuronal tissue after experimental traumatic brain injury in animal models. The blood-brain barrier is a critical structure that normally shields the brain from circulating blood components, and its breakdown after trauma is a central driver of cerebral edema, or swelling, which can be lethal. A companion study by Li and colleagues in the Journal of Neurochemistry the same year found that liraglutide was neurotrophic and neuroprotective in neuronal cultures and mitigated mild traumatic brain injury in mice, promoting neuronal survival and repair. An accompanying commentary by Combs asked directly whether GLP-1 receptor agonists might be useful against traumatic brain injury, capturing the excitement that these findings generated in the neurotrauma community.

What has been missing is human evidence. Animal models of brain injury have a notoriously poor track record of translating into effective treatments for patients, with numerous once-promising neuroprotective agents failing in clinical trials. The new study from the Taiwanese team therefore represents an important step in the translational chain, moving from rodent experiments to the analysis of real-world outcomes in surgically treated patients. By examining whether patients who were taking GLP-1 receptor agonists around the time of their brain injury surgery fared differently from those who were not, the researchers sought to test whether the laboratory promise of these drugs survives contact with clinical reality.

The study’s focus on surgically treated patients is notable for several reasons. First, this population represents a severe end of the traumatic brain injury spectrum, in which the injury burden is high enough to warrant operative management, and mortality risk is correspondingly elevated. Second, surgical patients are a relatively well-defined cohort, with clear timestamps for intervention, which helps researchers anchor their analyses. Third, as a TRACK-TBI study published in JAMA Surgery in 2024 by Roberts and colleagues demonstrated, exposure to extracranial surgery and the systemic effects of trauma and operations can significantly shape outcomes after brain injury, underscoring the importance of accounting for the overall clinical context when evaluating any potential therapeutic association. The new analysis, approved by an institutional review board and conducted without specific external funding, was published as a brief communication, a format typically reserved for concise, focused findings rather than large definitive trials.

The authors report an association between GLP-1 receptor agonist use and survival in this surgical population, a finding that, if confirmed, would suggest that the neuroprotective effects observed in the laboratory extend to humans. The researchers are careful to frame the work as an association study rather than a demonstration of causation. Patients who take GLP-1 receptor agonists are, by definition, a selected group, most commonly individuals with type 2 diabetes or obesity, and their underlying health profiles, comorbidities, and medical management differ in many ways from those of patients not taking the drugs. Disentangling whether any survival advantage stems from the drug itself, from better metabolic control, from differences in baseline health, or from some combination of these factors requires the kind of rigorous controlled comparison that only prospective randomized trials can provide. The authors declare no competing financial interests, and artificial intelligence was not used in the preparation of the manuscript.

Nevertheless, the implications of the finding are considerable. GLP-1 receptor agonists are among the most widely used medications in the world, with tens of millions of patients taking them for diabetes, obesity, and increasingly for cardiovascular and kidney protection. If even a modest survival benefit after traumatic brain injury were confirmed, the public health impact could be substantial, given the enormous global burden of head trauma from falls, road traffic collisions, and violence. The finding would also add to a rapidly expanding list of potential indications for this drug class, which researchers are already exploring in neurodegenerative disease, addiction, and other areas of neuroscience. The convergence of metabolic and neurological medicine, once a niche intersection, is becoming one of the most active frontiers in drug repurposing.

The path forward will likely involve several parallel efforts. Larger retrospective analyses across independent patient cohorts could test whether the association holds in different populations and health systems. Prospective studies could examine whether pre-injury GLP-1 receptor agonist use correlates with reduced cerebral edema, improved imaging markers, or altered inflammatory profiles in the acute phase of injury. Ultimately, randomized trials testing GLP-1-based therapy after brain injury, whether in patients already taking the drugs or as a new therapeutic intervention, would be needed to establish causation and define optimal timing, dosing, and patient selection. For now, the study stands as a compelling early signal that a drug class designed to treat metabolic disease may also help the injured brain survive, a possibility that laboratory scientists anticipated a decade ago and that clinical researchers are only now beginning to test in patients.

Subject of Research: Association between GLP-1 receptor agonist use and survival in surgically treated traumatic brain injury patients

Article Title: Association Between GLP-1 RECEPTOR Agonist use and Survival in Surgically Treated Patients with Traumatic Brain Injury

Article References: Khor, W.-T., Chi, K.-Y., Chang, Y., Perng, P.-S., Lin, H.-M., Huang, Y.-T., & Huang, C.-Y. (2026). Association Between GLP-1 RECEPTOR Agonist use and Survival in Surgically Treated Patients with Traumatic Brain Injury. Neurocritical Care. https://doi.org/10.1007/s12028-026-02676-z

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02676-z

Keywords: GLP-1 receptor agonists, traumatic brain injury, neuroprotection, survival, neurocritical care, liraglutide, blood-brain barrier, type 2 diabetes, neuroinflammation, drug repurposing, brain surgery, insulin signaling

The scale of the underlying clinical problem explains the intensity of the research effort. In 2024, an estimated 588.7 million adults worldwide were living with diabetes, more than 90 percent of them with the type 2 form, and prevalence is projected to reach 852.5 million by 2050. Type 2 diabetes is not merely a disorder of blood sugar: cardiovascular disease was reported in roughly a third of patients in a 13-country study, diabetic kidney disease affects up to 35 percent of patients and remains a leading cause of end-stage renal disease, and the frequent coexistence of obesity accelerates disease progression. These realities have pushed therapeutic priorities beyond short-term glycemic targets toward durable metabolic control, reduction of cardiovascular and renal risk, weight management and long-term treatment sustainability.

To chart the field’s development, the researchers searched the Web of Science Core Collection from January 2004 to December 2025, using a strategy that combined drug-class terms, generic and brand names of individual agents and disease-specific terms refined with proximity operators. Only original research articles in English were included, and two investigators independently screened all records against a predefined eligibility manual. The team then cleaned and standardized the data meticulously: country and institutional affiliations were harmonized, author keywords were consolidated across spelling and synonym variants, and drug names were standardized at two levels, merging formulations of the same agent for co-occurrence analyses while retaining regimen-level terms such as oral semaglutide for timeline and burst analyses. VOSviewer, CiteSpace and R handled the network construction, burst detection and statistical processing, and an independent PubMed search confirmed that more than 97 percent of the most-cited Web of Science articles were recoverable across databases.

The headline finding is explosive growth. Annual output rose from just 7 articles in 2004 to 589 in 2025. Studies restricted to selective GLP-1 receptor agonists accounted for 94.86 percent of the entire corpus, but studies involving GLP-1-based multi-receptor agonists, which engage additional metabolic hormone receptors, first appeared in 2020 and by 2025 together with mixed comparative studies made up 14.09 percent of that year’s output. The subject-category breakdown shows a literature spanning far beyond endocrinology and metabolism, which dominated at 55.03 percent, into pharmacology, general medicine, experimental medicine and cardiac and cardiovascular systems, reflecting the drugs’ widening clinical footprint.

Geographically, 80 countries and regions contributed, but the distribution was strikingly unequal. Under fractional counting, the ten most productive countries accounted for 79.01 percent of output, with the United States and China alone contributing 43.11 percent, and a country-level Gini coefficient of 0.837 signaled profound inequality. The United States led on nearly every measure, with 1,558 articles, 112,863 citations and the strongest collaboration links, while the United Kingdom and Denmark achieved higher citations per publication than the United States despite smaller outputs. China ranked second in publication volume but only tenth in total collaboration strength, and its multiple-country publication proportion was markedly lower than those of Germany, the United Kingdom, Canada and the Netherlands, illustrating that output, citation influence and collaboration intensity are distinct dimensions of national research performance.

The institutional analysis revealed a research ecosystem built around both pharmaceutical and academic hubs. Novo Nordisk and Eli Lilly ranked first and second in both full-counted publication output and total citations, with 426 and 343 articles and 43,640 and 32,211 citations respectively, and they remained the top two contributors even after fractional allocation of multi-institutional papers. Among academic centers, the University of Toronto, the University of Texas Southwestern Medical Center and the University of North Carolina stood out for citation impact. Institutional output followed a long-tailed distribution with a Gini coefficient of 0.682, yet the top ten institutions captured only 11.26 percent of fractional output, meaning no small group monopolized the field. At the author level, dispersion was even greater: the ten most productive researchers, led by Julio Rosenstock with 75 articles and a dataset-specific h-index of 41, accounted for just 1.62 percent of total fractional output, and 82 of 83 threshold-eligible authors formed a single connected co-authorship network of ten clusters.

The thematic evolution tells perhaps the most compelling story. Keyword co-occurrence analysis grouped the 100 most frequent author keywords into six clusters spanning incretin biology, individual therapies, glycemic management, obesity, cardiorenal complications and real-world evaluation. Timeline and burst analyses then revealed four developmental stages: a foundational period from 2004 to 2008 centered on incretin physiology and early exenatide trials; a therapeutic expansion phase from 2009 to 2015 dominated by liraglutide and the LEAD program; a cardiovascular-outcomes period from 2016 to 2020 shaped by landmark trials within a regulatory environment created by the 2008 US Food and Drug Administration cardiovascular-risk guidance; and, from 2021 onward, a phase of cardiovascular-kidney-metabolic integration featuring semaglutide, the dual GIP/GLP-1 agonist tirzepatide, obesity, chronic kidney disease, oral formulations and real-world evidence. Burst detection captured this shift quantitatively, with the strongest keyword burst belonging to GLP-1 itself from 2008 to 2018, and recent bursts for chronic kidney disease, fixed-ratio combination therapy and oral semaglutide extending through 2025.

Citation analysis confirmed which individual studies drove these transitions. When citations were normalized within publication year to remove the advantage of older papers, the LEADER trial of liraglutide by Marso and colleagues ranked first, with 6,891 total citations and a normalized score of 62.94, meaning it received nearly 63 times the mean citations of publications from the same year. The 2024 trial of semaglutide in patients with type 2 diabetes and chronic kidney disease ranked second despite its short citation window, followed by the REWIND dulaglutide trial and the head-to-head comparison of tirzepatide with semaglutide. Six of the top ten appeared in the New England Journal of Medicine and four in The Lancet. Among cited references, LEADER also produced the strongest citation burst, and the analysis showed influence migrating from early exenatide trials through the LEAD program and ADA/EASD consensus statements toward cardiorenal outcome trials and clinical guidance, with seven references still bursting through 2025.

The journal landscape added a further layer of nuance. The 3,736 articles were spread across 627 journals, but a recognizable specialty core emerged, led by Diabetes, Obesity and Metabolism with 494 articles, followed by Diabetes Therapy and Diabetes Care. Co-citation rankings told a different story: Diabetes Care was the most co-cited journal, but the New England Journal of Medicine and The Lancet were highly co-cited despite publishing few of the included articles, suggesting that landmark trials achieve their widest influence through general medical journals while the cumulative development of the evidence remains anchored in specialist outlets. Dual-map overlay analysis showed clinically oriented articles drawing on both molecular-biological and health-services literature, consistent with bidirectional translation between incretin biology, therapeutic development and outcomes research.

The authors are careful about what these bibliometric signals do and do not mean. Citation counts measure scholarly attention, not methodological quality or clinical benefit, and institutional prominence based on affiliations should not be read as evidence of funding involvement or commercial influence. They also note that the evidence base remains uneven: multi-receptor agonists other than tirzepatide, such as retatrutide and survodutide, have been studied mainly for short- to intermediate-term glycemic and weight outcomes, real-world data document substantial discontinuation and reinitiation, patient-experience research is strikingly thin, and racial, ethnic and socioeconomic disparities in trial participation and drug use persist. Combined with the geographic concentration documented here, these gaps suggest that the next phase of GLP-1 research will need to extend beyond efficacy and cardiovascular outcomes into long-term effectiveness, treatment persistence, equity and the populations and care settings that the current literature has largely left behind.

Subject of Research: Bibliometric analysis of research on GLP-1 receptor agonists and GLP-1-based multi-receptor agonists in type 2 diabetes mellitus

Article Title: Global Landscape and Thematic Evolution of Selective GLP‐1 Receptor Agonists and GLP‐1–Based Multi‐Receptor Agonists in Type 2 Diabetes Mellitus: A Bibliometric Analysis

Article References: Wang, Y., Liu, Z., Wang, S., Lv, C., El‐Seedi, H. R., Khalifa, S. A. M., & Wang, H. (2026). Global Landscape and Thematic Evolution of Selective GLP ‐1 Receptor Agonists and GLP ‐1–Based Multi‐Receptor Agonists in Type 2 Diabetes Mellitus: A Bibliometric Analysis. Endocrinology, Diabetes & Metabolism, 9(6), Article e70351. https://doi.org/10.1002/edm2.70351

Image Credits: AI Generated

DOI: 10.1002/edm2.70351

Keywords: GLP-1 receptor agonists, type 2 diabetes, bibliometrics, semaglutide, tirzepatide, liraglutide, cardiovascular outcomes, chronic kidney disease, obesity, incretin biology, research collaboration, citation analysis

The research, a multicentre, single-arm, post-marketing surveillance study sponsored by Novo Nordisk Pharma Taiwan, was designed deliberately to escape the artificial conditions of randomised controlled trials. Trials in the global SCALE program, which established liraglutide 3.0 mg as an effective adjunct to reduced-calorie diet and increased physical activity, operated under strict titration schedules, intensive monitoring, and exclusion criteria that often screened out patients with complex comorbidities. Real-world clinics face a messier reality: patients who hesitate to escalate doses, who discontinue early, or who cannot shoulder the financial burden of chronic therapy. By enrolling adults who had independently chosen to start liraglutide under approved label use, the Taiwanese investigators captured a pragmatic benchmark of what the drug actually delivers in everyday care.

The pharmacology behind liraglutide explains why it has captured such attention. The molecule shares 97 percent homology with human GLP-1, a gut hormone released after eating that travels to brain regions including the hypothalamus and amygdala, where it is translated into satiety and reduced food intake. Peripheral administration of the drug decreases caloric consumption, delays gastric emptying, stimulates insulin secretion, suppresses inappropriate glucagon release, improves pancreatic beta-cell function, and modestly increases energy expenditure, with the resulting weight loss coming primarily from reductions in fat mass. In the five adult trials of the SCALE program, the 3.0 mg dose consistently induced mean weight loss exceeding five percent of baseline body weight, superior to lifestyle modification alone, and the safety profile mirrored that of the 1.8 mg diabetes formulation, with transient gastrointestinal events reported most frequently.

What the Taiwanese team found was striking in its deviation from trial conditions. The mean daily dose actually administered was just 1.4 mg, well below the 3.0 mg maintenance target, and only 32 of the 259 participants, roughly 12 percent, ever escalated to the full recommended dose. Among the 227 participants who did not reach 3.0 mg, nearly half, 127 individuals, cited medication cost as the primary reason, while only eight cited adverse reactions. Nevertheless, in participants who persisted with treatment, the weight losses were unambiguous. At 13 weeks, the mean reduction was 5.7 kg, or 6.3 percent of baseline body weight, and at 26 weeks it reached 8.5 kg, or 9.1 percent, with both findings statistically significant at p less than 0.0001.

The proportions of patients crossing clinically meaningful thresholds were equally compelling. Among those treated for around 26 weeks, 76.7 percent lost at least five percent of their baseline body weight and 38.3 percent lost at least ten percent, results that align with prior studies of Asian populations showing clinically significant reductions even with submaximal doses over shorter treatment periods. The study population itself reflected the changing face of obesity in Taiwan, where adult obesity prevalence has climbed from 11.8 percent in the mid-1990s to 23.9 percent by 2020. Sixty-one percent of participants were women, the mean age was 42 years, the mean baseline BMI was 33.0 kg per square metre, and comorbidities were common, including dyslipidaemia in 38 percent, hepatic impairment in 27 percent, hypertension in 26 percent, and diabetes in 21 percent.

On safety, the surveillance data painted a picture arguably more favourable than the trial literature, though the investigators urge caution in direct comparison. Only 29 participants, 11.2 percent, experienced any adverse event, with 44 events recorded in total. Gastrointestinal disorders, classically the dominant side effect of GLP-1 therapy, accounted for just 2.3 percent of the cohort, comprising constipation, nausea, abdominal distension, diarrhoea, and stomatitis, and no gastrointestinal event progressed to serious complications such as cholelithiasis, cholecystitis, or pancreatitis. General disorders and injection-site conditions, including erythema, dermatitis, hypersensitivity, and pruritus, were the most frequent category at 4.3 percent. Only three events were rated moderate and one severe, no serious adverse drug reactions were documented, and only eight participants discontinued treatment because of intolerable adverse events.

The investigators attribute the low event rates to several converging factors. Lower doses plausibly produce fewer dose-dependent effects, consistent with exposure-response analyses showing that higher liraglutide concentrations correlate with more nausea and vomiting. Slower, more flexible titration schedules chosen by clinicians may have allowed patients to develop better tolerance. Spontaneous reporting in observational settings likely under-documented mild events, and the large proportion of participants, nearly 46 percent, who withdrew before week 13 may have removed transient adverse events from the final tally. The shorter 26-week duration, compared with the 52 to 56 weeks of pivotal trials, may also have excluded late-onset serious events. Notably, subgroup analyses found no statistically significant differences in adverse event incidence across sex, age, comorbidities, hepatic impairment, or concomitant use of other anti-obesity medications, suggesting a consistent safety profile across patient types.

Beyond weight, the study detected a moderate reduction in blood pressure, more pronounced in systolic pressure, corroborating earlier liraglutide findings. Physiological studies suggest a mechanism rooted in renal GLP-1 receptor activation, which promotes urinary sodium excretion and natriuresis. Given that the mean baseline systolic pressure in this cohort, 134.8 mmHg, exceeded that of previous trials, the authors suggest liraglutide holds potential for integration into hypertension management for adults with obesity in Taiwan, and possibly a broader role in cardiovascular comorbidities associated with chronic metabolic disease, such as coronary artery disease.

Perhaps the most consequential finding is economic rather than pharmacological. With cost, not tolerability, driving both dose limitation and discontinuation, the study highlights an urgent need for health financing reform, including possible National Health Insurance subsidies for GLP-1 receptor agonists approved for weight loss in Taiwan. Modelled projections suggest these drugs may reduce lifetime societal costs of obesity, though comparative analyses in the United Kingdom and the United States have found newer agents such as semaglutide and tirzepatide more cost-effective than liraglutide. The authors acknowledge their study’s limitations, including the absence of a control group, per-protocol analysis that may overestimate effectiveness, attrition bias, and a short observation window, but they conclude that submaximal liraglutide doses achieved weight reductions comparable to the 3.0 mg dose in prior trials while reducing adverse events and financial burden, a combination that could reshape how this class of drugs is prescribed, priced, and sustained in the world’s fastest-growing obesity epidemic.

Subject of Research: A multicentre post-marketing surveillance study evaluating the real-world safety and effectiveness of liraglutide for weight management in adults with obesity in Taiwan.

Article Title: Liraglutide in Adults With Obesity: A Multicentre, Single‐Arm, Post‐Marketing Surveillance Study in Taiwan

Article References: Liraglutide in Adults With Obesity: A Multicentre, Single‐Arm, Post‐Marketing Surveillance Study in Taiwan. (n.d.). https://doi.org/10.1002/edm2.70333

Image Credits: AI Generated

DOI: 10.1002/edm2.70333

Keywords: liraglutide, obesity, GLP-1 receptor agonist, weight loss, Taiwan, post-marketing surveillance, anti-obesity medication, real-world evidence, gastrointestinal adverse events, medication cost, blood pressure, type 2 diabetes

The analysis, conducted according to PRISMA 2020 standards, drew its evidence from the major Phase 3 programs that defined the modern incretin era: SURMOUNT, testing tirzepatide; STEP, testing injectable semaglutide; SCALE, testing liraglutide 3.0 mg; and OASIS, testing oral semaglutide. From an initial pool of 878 records, independent reviewers narrowed the field to 19 randomized controlled trials meeting strict criteria, including a minimum duration of 12 weeks and standardized body composition or nutritional laboratory measurements. High-potency therapy was defined as any agent or dose producing at least 10 percent mean total body weight reduction, a threshold met by all tirzepatide doses, injectable semaglutide at 1.0 mg or above, and oral semaglutide 50 mg. Liraglutide 3.0 mg was classified as a moderate-potency comparator but retained because the SCALE program remains the only Phase 3 dataset with longitudinal pancreatic enzyme measurements.

The mechanistic foundation of the findings lies in the sheer magnitude of caloric suppression these drugs produce. Once-daily oral semaglutide 50 mg reduced energy intake by a relative 39.20 percent by week 20, translating to a deficit of roughly 1009 kilojoules, about 241 calories, during a single ad libitum lunch compared with placebo. Across the synthesized trials, metabolic models estimated daily energy deficits reaching 1200 kilocalories from baseline, while tirzepatide 15 mg produced a consistent 348.40 kilocalorie per day reduction. Meta-analysis of continuous intake data confirmed this suppression was statistically robust. Critically, these deficits occurred alongside shifts in food preference: participants on tirzepatide showed significant decreases in 10 of 12 food preference categories, blunting desire for high-fat and high-sugar items. The hedonic blunting that helps patients eat less may simultaneously suppress the biological hunger signals that normally correct for emerging nutrient gaps.

Body composition data revealed a second dimension of concern. Across drug classes, fat-free mass, the non-adipose component of body weight that includes muscle, bone, organs, and fluids, declined significantly. Tirzepatide 15 mg was associated with a mean fat-free mass reduction of 1.60 kg, representing 14.30 percent of total weight lost, while semaglutide 1.0 mg produced a 0.80 kg decline constituting 11.60 percent of weight reduction. The researchers emphasize that fat-free mass is not synonymous with skeletal muscle mass, and only one mechanism-of-action study reported appendicular lean mass as a muscle proxy. Even so, the proportional loss of lean tissue raises the prospect of sarcopenic obesity, a condition combining reduced muscle mass with metabolic dysfunction. The risk is sharpened by the finding that 7.26 percent of participants crossed a body mass index below 22 kg/m2, a threshold at which clinical protocols recommend modifying intake to prevent physical frailty.

The contrast between clinical reporting and laboratory reality forms the analytical centerpiece of the review. Pooled analysis of MedDRA-coded malnutrition events across the SURMOUNT 1-4 trials produced a non-significant risk ratio of 2.38, suggesting standard adverse event capture missed most nutritional deterioration. Total lymphocyte count below 910 per microliter, a marker independently associated with impaired immune function, delayed wound healing, and increased infection susceptibility, appeared in 2.90 percent of active therapy participants, nearly double the placebo rate, with a statistically significant risk ratio of 1.64. Meanwhile, 0.38 percent of tirzepatide-treated participants reached an underweight classification during treatment, and investigator-reported vitamin deficiencies involving vitamin D, B12, and folate occurred in 0.99 percent, though none of the original protocols screened for these systematically at predetermined intervals.

Secondary metabolic stressors add another layer of physiological complexity. Pooled SCALE data documented a mean 31 percent increase in pancreatic lipase and 7 percent increase in amylase following liraglutide treatment, elevations that appeared early, persisted during therapy, were dose-independent, and reversed upon drug cessation. Although 12 cases of acute pancreatitis were confirmed in liraglutide arms, a 0.4 percent incidence, the positive predictive value of enzyme elevations alone was below 1 percent, indicating these biomarkers more likely represent subclinical pancreatic stress than acute inflammation. Whether comparable enzyme dynamics occur with tirzepatide or injectable semaglutide remains unknown, because neither the SURMOUNT nor STEP programs included pancreatic enzyme monitoring. Persistent subclinical pancreatic stress could theoretically introduce a malabsorptive component, potentially compromising fat-soluble vitamin status even in patients with adequate intake.

Individual variability in baseline physiology may determine who is most vulnerable. Deep-phenotyping research describes a ‘Calories to Satiation’ trait ranging from 140 to 2166 kilocalories among adults with obesity, and high-potency incretins may amplify this gut-brain axis signal to its maximum effect. People who already reach satiation at low caloric intakes could ‘overshoot’ intended restriction, a concern compounded by sex differences, since women generally reach satiation at lower energy intakes than men. In trials with predominantly female enrollment, such as SURMOUNT-1 at 67 percent and STEP 1 at 74 percent female, the observed magnitude of lean mass loss may partly reflect this lower baseline caloric threshold. Bone health introduces a further unmeasured dimension: rapid weight loss removes the mechanical loading stimulus that sustains bone mineral density in obesity, and bariatric surgery studies document significant bone loss within 12 to 24 months. No included trial measured bone density, leaving the skeletal consequences of drug-induced weight loss entirely unquantified.

To translate these findings into clinical practice, the researchers propose a Tiered Stepped-Care Algorithm built on the 1200 kilocalorie daily deficit as the mechanistic anchor. Step one mandates baseline screening for albumin, total lymphocyte count, and vitamin D to identify pre-existing vulnerabilities. Step two requires periodic monitoring of the deficit threshold alongside body composition shifts to detect excessive lean mass attrition. Step three activates intensive intervention, with immediate referral for Medical Nutrition Therapy, when serum albumin falls below 3.3 g/dL or total lymphocyte count drops below 910 per microliter. The framework mirrors nutritional oversight long considered standard for bariatric surgery patients, a population whose weight loss trajectories are comparable in magnitude to those produced by maximum-dose tirzepatide, which achieved 22.5 percent total body weight loss over 72 weeks in SURMOUNT-1.

The authors acknowledge important limitations. The original Phase 3 programs were designed to demonstrate weight loss efficacy and cardiometabolic safety, not nutritional outcomes, so reliance on post-hoc analyses likely underestimates true malnutrition prevalence. The 12-week minimum duration criterion may have excluded shorter mechanistic studies, the predominantly East Asian population in SURPASS-AP-Combo, with lower baseline body mass indices, limits generalizability to Western cohorts, and publication bias could not be excluded from secondary endpoints. Quality assessment using the Cochrane Risk-of-Bias tool found low risk across all major domains for the included programs, and Egger regression detected no significant publication bias for the primary outcome. Future trials, the researchers argue, should incorporate pre-specified dual-energy X-ray absorptiometry monitoring, serum micronutrient panels, fecal elastase testing, head-to-head comparisons in adults aged 65 and older with sarcopenia and bone density as co-primary outcomes, and follow-up of at least two years. Sustained weight reduction remains a legitimate therapeutic goal, the analysis concludes, but the data suggest it should no longer be pursued without the nutritional surveillance needed to protect the physiological integrity of the millions of patients now taking these medications.

Subject of Research: Systematic review and meta-analysis of malnutrition risk, energy restriction, and lean mass loss in high-potency incretin therapy

Article Title: A Systematic Review and Meta‐Analysis of Malnutrition and Metabolic Failure in High‐Potency Incretin Therapy

Article References: Ampofo, E., Apprey, C., Amoako, M., & Turkson, F. D. (2026). A Systematic Review and Meta‐Analysis of Malnutrition and Metabolic Failure in High‐Potency Incretin Therapy. Obesity Science & Practice, 12(5), Article e70188. https://doi.org/10.1002/osp4.70188

Image Credits: AI Generated

DOI: 10.1002/osp4.70188

Keywords: incretin therapy, semaglutide, tirzepatide, liraglutide, malnutrition, fat-free mass, weight loss, obesity, GLP-1 receptor agonists, nutritional monitoring, sarcopenia, meta-analysis

The mechanistic foundations of the three drugs explain much of their divergent behaviour. Semaglutide is a human GLP-1 analog with 94 percent sequence identity to the native hormone, engineered with an Aib substitution at position 8 to resist degradation by the enzyme DPP-4 and a C18 fatty diacid side chain at position 26 that binds albumin and extends its half-life to roughly seven days. Liraglutide, with 97 percent homology, carries a shorter C16 palmitic acid chain that yields a half-life of about 13 hours, confining it to once-daily injection. Tirzepatide, a 39-amino-acid synthetic ‘twincretin’, activates both the GIP and GLP-1 receptors and carries a C20 fatty diacid moiety that prolongs systemic exposure to approximately five days. These structural choices dictate dosing convenience, adherence and, ultimately, how patients experience therapy.

Formulation differences add a practical dimension to drug selection. Semaglutide is the only agent in the class available as an oral tablet, made possible by the absorption enhancer SNAC, though oral bioavailability is only about one percent and the tablet must be taken fasting with water only. Subcutaneous semaglutide achieves roughly 89 percent bioavailability. Liraglutide requires daily subcutaneous injection, which may deter some patients, while tirzepatide is delivered exclusively as a once-weekly autoinjector. Real-world data show semaglutide achieves approximately 40 percent treatment persistence at one year, higher than liraglutide, and tirzepatide’s weekly dosing is expected to support strong adherence, though long-term real-world outcomes remain pending. Notably, liraglutide is the only one of the three approved for adolescents with both type 2 diabetes and obesity.

On glycaemic control, the review’s synthesis of trial data reveals a clear hierarchy. Subcutaneous semaglutide at 0.5 to 1.0 mg reduced HbA1c by 1.3 to 1.8 percent across the SUSTAIN program, outperforming placebo, sitagliptin, exenatide and basal insulin, while oral semaglutide achieved reductions of 1.3 to 2.0 percent in the PIONEER trials, edging out subcutaneous liraglutide 1.8 mg in PIONEER 4. Liraglutide, tested in the LEAD program at 1.2 and 1.8 mg, produced HbA1c reductions of 0.7 to 1.5 percent. Tirzepatide, however, set a new benchmark: in SURPASS-2, doses of 5, 10 and 15 mg lowered HbA1c by approximately 2.01, 2.24 and 2.30 percent respectively, surpassing semaglutide 1 mg, which achieved 1.86 percent. Pooled analyses indicate more than 90 percent of tirzepatide recipients reached the HbA1c target below 7.0 percent.

Weight outcomes follow a similar pattern. Semaglutide 2.4 mg weekly produced mean weight losses of up to 14.9 percent at 68 weeks in the STEP program and 10.2 percent over four years in the SELECT trial, accompanied by a 7.7 cm reduction in waist circumference. Liraglutide at 3.0 mg daily achieved approximately 4.91 kg of weight loss in meta-analysis, with BMI declines and waist reductions around 3.55 cm. Tirzepatide again led the field: SURPASS trials recorded weight reductions ranging from 5.3 to 17.1 kg depending on dose and comparator, and in the SURMOUNT-4 trial participants with obesity maintained mean reductions of approximately 20.9 percent at 88 weeks. A SURPASS-3 substudy further showed tirzepatide reduced hepatic fat and visceral adipose tissue, with waist circumference falling by up to 18.5 cm at the highest dose.

Lipid modulation, a subtler but clinically relevant domain, also favoured the dual agonist. Semaglutide produced modest reductions of roughly 3 to 6 percent in total cholesterol, 5 to 10 percent in LDL cholesterol and 10 to 15 percent in triglycerides, with slight HDL increases, mechanisms attributed to reduced free fatty acid influx to the liver and enhanced lipoprotein lipase activity. Liraglutide showed mild improvements, particularly in triglycerides and apolipoprotein B, with dose-dependent variability. Tirzepatide delivered the most pronounced effects: meta-analytic estimates showed triglyceride reductions of 13 to 22 percent, total cholesterol reductions of roughly 5 to 7 percent, and HDL increases of 4 to 7 percent, alongside reductions in large triglyceride-rich lipoproteins and small LDL particles. The authors caution, however, that these are surrogate markers whose translation into fewer cardiovascular events remains unproven.

Where hard clinical outcomes exist, the picture becomes more differentiated. In the SUSTAIN-6 cardiovascular outcomes trial, semaglutide reduced three-point major adverse cardiovascular events—cardiovascular death, nonfatal myocardial infarction and nonfatal stroke—by 26 percent, with post hoc analyses suggesting a roughly 35 percent reduction in stroke incidence, the strongest cerebrovascular signal in the class. Liraglutide, in the landmark LEADER trial, achieved a 13 percent MACE reduction driven primarily by significant reductions in cardiovascular death, making it particularly relevant for patients whose dominant risk is mortality. Tirzepatide has not yet completed a dedicated outcomes trial, but a pre-specified meta-analysis of pooled SURPASS data, including the high-risk SURPASS-4 cohort, reported a 27 percent relative risk reduction in three-point MACE and a 46 percent reduction in four-point MACE—promising signals awaiting confirmation from the ongoing SURPASS-CVOT.

Kidney outcomes reveal mechanistic distinctions with direct clinical implications. Semaglutide cut the risk of new or worsening nephropathy by 36 percent in SUSTAIN-6, slowed eGFR decline in pooled analyses, and extended renal protection to non-diabetic individuals with cardiovascular disease in the SELECT trial, suggesting partially glucose-independent benefit. Liraglutide reduced nephropathy risk by 22 percent in LEADER, but its effect appears largely mediated by improved glycaemic control and blood pressure rather than direct nephroprotection. Tirzepatide, studied in SURPASS-4’s chronic kidney disease cohort, attenuated eGFR decline and reduced macroalbuminuria across all doses, and causal mediation analysis indicated that only 40 to 60 percent of the renal benefit was explained by traditional factors such as HbA1c, blood pressure and weight—implying a substantial glucose-independent component that may make it especially valuable for patients with diabetic kidney disease.

Safety profiles across the class are broadly favourable, dominated by gastrointestinal effects. Nausea, vomiting and diarrhoea are common with all three agents, typically arising during dose escalation and subsiding within four to eight weeks with gradual titration. Tirzepatide produces the highest frequency and severity of gastrointestinal events, including constipation, likely reflecting its GIP receptor activity, followed by semaglutide and then liraglutide, which tends to cause milder, more gradual symptoms. Gallbladder events such as cholelithiasis have been observed with all agents, largely associated with rapid weight loss, and pancreatitis is rare. Hypoglycaemia is uncommon unless the drugs are combined with insulin or sulfonylureas. All three are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. In renal impairment, tirzepatide maintains stable pharmacokinetics even in dialysis patients, an advantage over semaglutide and liraglutide, which require caution in end-stage renal disease.

The review’s overarching conclusion is a call for calibrated clinical judgement rather than a declaration of winners. Tirzepatide demonstrably offers the greatest HbA1c and weight reductions, semaglutide combines substantial efficacy with formulation flexibility and the best stroke evidence, and liraglutide provides a proven mortality benefit with the broadest paediatric indication. Yet because every comparison in the analysis is indirect—drawn from separate trials with different populations, comparators and endpoints—the authors insist the findings should be treated as hypothesis-generating, not definitive proof of superiority. They identify direct head-to-head trials, particularly tirzepatide versus higher-dose semaglutide, long-term cardiovascular and renal outcome data for tirzepatide, and evidence in underrepresented populations as critical gaps. Until those trials report, treatment decisions must remain individualized, weighing comorbidities, renal function, tolerability, dosing preferences and each patient’s therapeutic priorities.

Subject of Research: Comparative cardiometabolic effects of the incretin-based therapies semaglutide, liraglutide and tirzepatide in type 2 diabetes and obesity

Article Title: Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review

Article References: Bawadi, H., Abuhijleh, H., Nofal, M., Zakaria, Z. Z., & Al‐Asmakh, M. (2026). Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review. Endocrinology, Diabetes & Metabolism, 9(5), Article e70338. https://doi.org/10.1002/edm2.70338

Image Credits: AI Generated

DOI: 10.1002/edm2.70338

Keywords: semaglutide, liraglutide, tirzepatide, GLP-1 receptor agonists, type 2 diabetes, obesity, HbA1c, weight loss, cardiovascular outcomes, renal function, lipid profile, incretin therapies